Potential impact of introducing vaccines against COVID-19 under supply and uptake constraints in France: A modelling study

• Published in: PloS one Vol. 16; no. 4; p. e0250797
• Main Authors: Coudeville, Laurent, Jollivet, Ombeline, Mahé, Cedric, Chaves, Sandra, Gomez, Gabriela B
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 28.04.2021; Public Library of Science (PLoS)
• Subjects: Acceptance tests; Biology and Life Sciences; Calibration; Clinical trials; Constraint modelling; Control; Coronaviruses; COVID-19; COVID-19 vaccines; Data science; Disease prevention; Disease transmission; Economic aspects; Epidemics; Epidemiology; Hospitalization; Immunization; Infections; Medicine and Health Sciences; Optimization; Pandemics; Population; Research and Analysis Methods; Severe acute respiratory syndrome coronavirus 2; Statistics; Vaccination; Vaccine development; Vaccines; France; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0250797

The accelerated vaccine development in response to the COVID-19 pandemic should lead to a vaccine being available early 2021, albeit in limited supply and possibly without full vaccine acceptance. We assessed the short-term impact of a COVID-19 immunization program with varying constraints on population health and non-pharmaceutical interventions (NPIs) needs. A SARS-CoV-2 transmission model was calibrated to French epidemiological data. We defined several vaccine implementation scenarios starting in January 2021 based on timing of discontinuation of NPIs, supply and uptake constraints, and their relaxation. We assessed the number of COVID-19 hospitalizations averted, the need for and number of days with NPIs in place over the 2021-2022 period. An immunisation program under constraints could reduce the burden of COVID-19 hospitalizations by 9-40% if the vaccine prevents against infections. Relaxation of constraints not only reduces further COVID-19 hospitalizations (30-39% incremental reduction), it also allows for NPIs to be discontinued post-2021 (0 days with NPIs in 2022 versus 11 to 125 days for vaccination programs under constraints and 327 in the absence of vaccination). For 2021, COVID-19 control is expected to rely on a combination of NPIs and the outcome of early immunisation programs. The ability to overcome supply and uptake constraints will help prevent the need for further NPIs post-2021. As the programs expand, efficiency assessments will be needed to ensure optimisation of control policies post-emergency use.